Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

SIMPLE SUMMARY: Clinical trials for new drugs to treat rare diseases are difficult to evaluate due to the limited patient population available for recruitment. Growth modulation index (GMI) is a very useful tool in these instances, as this calculation compares the patient’s outcome on the current dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Italiano, Antoine, Nanda, Shivani, Briggs, Andrew, Garcia-Foncillas, Jesus, Lassen, Ulrik, Vassal, Gilles, Kummar, Shivaani, van Tilburg, Cornelis M., Hong, David S., Laetsch, Theodore W., Keating, Karen, Reeves, John A., Fellous, Marc, Childs, Barrett H., Drilon, Alexander, Hyman, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692104/
https://www.ncbi.nlm.nih.gov/pubmed/33158040
http://dx.doi.org/10.3390/cancers12113246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692104/
https://www.ncbi.nlm.nih.gov/pubmed/33158040
http://dx.doi.org/10.3390/cancers12113246

Ejemplares similares